BrainStorm announces Nasdaq delisting and transition to OTCQB
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 17 2025
0mins
Should l Buy ?
Delisting Notification: BrainStorm Cell Therapeutics has received a notification from Nasdaq that its common stock will be delisted due to non-compliance with the minimum shareholder equity requirement, effective July 18.
Transition to OTCQB: The company has secured approval to have its shares quoted on the OTCQB Venture Market under the same symbol, BCLI, starting July 18 or shortly thereafter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
